{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T14:43:51Z","timestamp":1779374631041,"version":"3.53.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"am","delay-in-days":333,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100006293","name":"American Society of Clinical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006293","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018937","name":"Bavarian Nordic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018937","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["ZIABC011528"],"award-info":[{"award-number":["ZIABC011528"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.urolonc.2025.06.006","type":"journal-article","created":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T20:45:29Z","timestamp":1754599529000},"page":"660.e1-660.e10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Bacillus Calmette-Gu\u00e9rin (BCG) in combination with PANVAC\u2122 vs. BCG alone in adults with high-grade BCG-refractory non-muscle-invasive bladder cancer"],"prefix":"10.1016","volume":"43","author":[{"given":"Matthew","family":"Ho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alon","family":"Lazarovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ragheed","family":"Saoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8314-4576","authenticated-orcid":false,"given":"Aaron","family":"Dahmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Tremblay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siobhan","family":"Telfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahir","family":"Maruf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric A.","family":"Singer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert E.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas L.","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sammy E.","family":"Elsamra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Merino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Dolan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Valera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz Walter","family":"Rodriquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reema","family":"Railkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Bellfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lambros","family":"Stamatakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renee N.","family":"Donahue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesar Pico","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea B.","family":"Apolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L.","family":"Gulley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Schlom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piyush K.","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2025.06.006_bib0001","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s40273-014-0194-2","article-title":"The health economics of bladder cancer: an updated review of the published literature","volume":"32","author":"Yeung","year":"2014","journal-title":"Pharmacoeconomics"},{"issue":"10061","key":"10.1016\/j.urolonc.2025.06.006_bib0002","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1016\/S0140-6736(16)30512-8","article-title":"Bladder cancer","volume":"388","author":"Kamat","year":"2016","journal-title":"Lancet Lond Engl"},{"issue":"4","key":"10.1016\/j.urolonc.2025.06.006_bib0003","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.06.006_bib0004","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/00005392-199707000-00017","article-title":"The treated natural history of high risk superficial bladder cancer: 15-year outcome","volume":"158","author":"Cookson","year":"1997","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2025.06.006_bib0005","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1002\/cncr.24914","article-title":"Gemcitabine versus bacille Calmette-Gu\u00e9rin after initial bacille Calmette-Gu\u00e9rin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial","volume":"116","author":"Di Lorenzo","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2025.06.006_bib0006","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/S0022-5347(17)42722-4","article-title":"Results of 6 weekly intravesical bacillus Calmette- Guerin instillations on the treatment of superficial bladder tumors","volume":"139","author":"Kavoussi","year":"1988","journal-title":"J Urol"},{"issue":"10064","key":"10.1016\/j.urolonc.2025.06.006_bib0007","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin- ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"The Lancet"},{"issue":"1","key":"10.1016\/j.urolonc.2025.06.006_bib0008","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open- label, repeat-dose clinical trial","volume":"22","author":"Boorjian","year":"2021","journal-title":"Lancet Oncol"},{"issue":"16_suppl","key":"10.1016\/j.urolonc.2025.06.006_bib0009","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.4508","article-title":"Final clinical results of pivotal trial of IL-15R\u03b1Fc superagonist N-803 with BCG in BCG-unresponsive CIS and papillary nonmuscle-invasive bladder cancer (NMIBC)","volume":"40","author":"Chamie","year":"2022","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.urolonc.2025.06.006_bib0010","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/j.1464-410X.1994.tb07514.x","article-title":"Mucin expression by transitional cell carcinomas of the bladder","volume":"73","author":"Walsh","year":"1994","journal-title":"Br J Urol"},{"issue":"3 Suppl","key":"10.1016\/j.urolonc.2025.06.006_bib0011","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1002\/1097-0142(197809)42:3+<1546::AID-CNCR2820420829>3.0.CO;2-D","article-title":"Immunocytochemical detection of carcinoembryonic antigen in conventional histopathology specimens","volume":"42","author":"Goldenberg","year":"1978","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.urolonc.2025.06.006_bib0012","first-page":"225","article-title":"Epidermal growth factor receptor, MUC-1 and MUC-2 in bladder cancer","volume":"19","author":"Cardillo","year":"2000","journal-title":"J Exp Clin Cancer Res CR"},{"issue":"6","key":"10.1016\/j.urolonc.2025.06.006_bib0013","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1097\/SLA.0b013e318292919e","article-title":"A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer","volume":"258","author":"Morse","year":"2013","journal-title":"Ann Surg"},{"issue":"8","key":"10.1016\/j.urolonc.2025.06.006_bib0014","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1001\/jamaoncol.2015.2736","article-title":"Docetaxel alone or in combination with a therapeutic cancer vaccine (PANVAC) in patients with metastatic breast cancer: a randomized clinical trial","volume":"1","author":"Heery","year":"2015","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.06.006_bib0015","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.eururo.2018.09.028","article-title":"Prognostic Implication of the United States Food and Drug Administration-defined BCG-unresponsive Disease","volume":"75","author":"Li","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.06.006_bib0016","doi-asserted-by":"crossref","DOI":"10.1158\/2326-6066.CIR-15-0119","article-title":"Phase i trial of a yeast-based therapeutic cancer vaccine (GI-6301) targeting the transcription factor brachyury","author":"Heery","year":"2015","journal-title":"Cancer Immunol Res"},{"issue":"16","key":"10.1016\/j.urolonc.2025.06.006_bib0017","doi-asserted-by":"crossref","first-page":"4933","DOI":"10.1158\/1078-0432.CCR-19-0183","article-title":"A phase I dose-escalation trial of BN-CV301, a recombinant poxviral vaccine targeting MUC1 and CEA with costimulatory molecules","volume":"25","author":"Gatti-Mays","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.urolonc.2025.06.006_bib0018","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1159\/000446495","article-title":"Development of cancer vaccines targeting brachyury, a transcription factor associated with tumor EMT","volume":"203","author":"Hamilton","year":"2017","journal-title":"Cells Tiss Organs"},{"key":"10.1016\/j.urolonc.2025.06.006_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2024.01.019","article-title":"Standardization of the evaluation and surveillance of patients with BCG unresponsive high grade non-muscle invasive bladder cancer clinical trials","author":"Lotan","year":"2024","journal-title":"Urol Oncol"},{"issue":"16","key":"10.1016\/j.urolonc.2025.06.006_bib0020","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1200\/JCO.2015.64.4070","article-title":"Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group","volume":"34","author":"Kamat","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2025.06.006_bib0021","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/bju.16087","article-title":"Bacillus Calmette\u2013Gu\u00e9rin (BCG) unresponsive non-muscle-invasive bladder cancer: are the subgroups equal?","volume":"132","author":"Tan","year":"2023","journal-title":"BJU Int"},{"issue":"7","key":"10.1016\/j.urolonc.2025.06.006_bib0022","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","article-title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study","volume":"22","author":"Balar","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2025.06.006_bib0023","unstructured":"Necci A., et al. SunRISe-1: TAR-200 monotherapy in patients with BCG unresponsive high-risk non\u2013Muscle-invasive bladder cancer (HR NMIBC). Abstract presented at 2023 ESMO October 20-24, 2023; Madrid, Spain"},{"key":"10.1016\/j.urolonc.2025.06.006_bib0024","unstructured":"Tyson M., Uchio E., Nam J., et al. First results from BOND-003: phase 3 study of Cretostimogene Grenadenorepvec monotherapy for patients with BCG unresponsive high-risk NMIBC with CIS \u00b1 papillary (Ta\/T1) tumors. Abstract presented at 2023 Society of Urologic Oncology November 28 - December 1 2023; Washington, DC."},{"issue":"1","key":"10.1016\/j.urolonc.2025.06.006_bib0025","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.eururo.2021.12.005","article-title":"International bladder Cancer group consensus statement on clinical trial design for patients with Bacillus Calmette-Gu\u00e9rin\u2013 exposed high-risk non\u2013muscle-invasive bladder cancer","volume":"82","author":"Roumigui\u00e9","year":"2022","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2025.06.006_bib0026","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s00262-022-03274-6","article-title":"Phase II trial of CV301 vaccine combined with atezolizumab in advanced urothelial carcinoma","volume":"72","author":"Sonpavde","year":"2023","journal-title":"Cancer Immunol Immunother CII"},{"issue":"NOV","key":"10.1016\/j.urolonc.2025.06.006_bib0027","article-title":"Intravesical gemcitabine versus intravesical bacillus calmette-gu\u00e9rin for the treatment of non-muscle invasive bladder cancer: an evaluation of efficacy and toxicity","volume":"7","author":"Prasanna","year":"2017","journal-title":"Front Oncol"},{"key":"10.1016\/j.urolonc.2025.06.006_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2012.10.039","article-title":"Final results of an EORTC-GU cancers group randomized study of maintenance bacillus calmette-gu\u00e9rin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance","author":"Oddens","year":"2013","journal-title":"Eur Urol."},{"issue":"1","key":"10.1016\/j.urolonc.2025.06.006_bib0029","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/iju.13410","article-title":"Intravesical bacillus Calmette-gu\u00e9rin instillation in non-muscle- invasive bladder cancer: a review","volume":"25","author":"Saluja","year":"2018","journal-title":"Int J Urol"},{"key":"10.1016\/j.urolonc.2025.06.006_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/S0022-5347(17)43959-0","article-title":"Risks and benefits of repeated courses of intravesical bacillus Calmette-Gurerin therapy for superficial bladder cancer","author":"Catalona","year":"1987","journal-title":"J Urol."}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925002224?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925002224?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T06:13:25Z","timestamp":1759299205000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143925002224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":30,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1078143925002224"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.06.006","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bacillus Calmette-Gu\u00e9rin (BCG) in combination with PANVAC\u2122 vs. BCG alone in adults with high-grade BCG-refractory non-muscle-invasive bladder cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}